BRCA1 and familial pancreatic carcinoma: This evidence offers the validity of routine sequencing of not only BRCA1/2 but also of the wide range of HR-related genes as part of biological characterization and for treatment decisions using PARPi, at least in the cases of breast and pancreatic cancer.